Secukinumab (Cosentyx)
Adolescent hidradenitis suppurativa (HS) Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adolescents 12 years and older with an inadequate response to conventional systemic HS therapy (see section 5.1).
In two phase 3 trials in moderate-to-severe hidradenitis suppurativa, secukinumab every 2 weeks improved week-16 clinical response vs placebo (45% vs 34%; 42% vs 31%); every 4 weeks was significant only in SUNRISE (46% vs 31%), not SUNSHINE (42% vs 34%). RCT · phase 3 · n = 1,084 · Lancet · 2023
In week 52 responders with moderate-to-severe hidradenitis suppurativa, randomised withdrawal to placebo vs continued secukinumab did not meet the primary endpoint of time to loss of response (risk reduction 13%, P=0.25 every 2 weeks; 30%, P=0.04 every 4 weeks). RCT · phase 3 · Br J Dermatol · 2025